All In Biotech

Drug Trial Radar · NCT05882695

Study of SPG302 in Healthy Volunteers and ALS Participants

A Phase 1/2a, Randomized, Double Blind, Placebo Controlled, Single and Multiple Dose Escalation Study in Healthy Volunteers and an Expansion Cohort in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302

Last checked: Nov 19, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

88

Actual

Start

Jul 3, 2023

Primary completion

Jun 27, 2025

Study completion Jun 27, 2025

Sponsor

Lead sponsor
SpinogenixIndustry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
May 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The first-in-human Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • SPG302Drug

    synthetic small molecule

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability in healthy volunteers (SAD cohort)Time frame: 7 days
  2. Safety and tolerability in healthy volunteers (SAD food effect cohort)Time frame: 15 days
  3. Safety and tolerability in healthy volunteers (MAD cohort)Time frame: 12 days
  4. Safety and tolerability in participants with ALSTime frame: 60 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Macquarie University

    North Ryde, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Flinders Medical center

    Adelaide, South Australia, Australia

  • Nucleus Melbourne (healthy volunteers)

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.